Monitoring side-effects to psychiatric medicines in patients with intellectual disability

Mental Health Aspects of Developmental Disabilities

Volumn 9, Issue 4, 2006, Pages 128-130

  Pary, Robert J ^a   Hurley, Anne DesNoyers ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIMS; Antipsychotic; Developmental; Intellectual disability; Mental retardation; Side effects; Tardive dyskinesia

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ACNE; CONFUSION; DIABETES MELLITUS; GAIT DISORDER; HAIR LOSS; HUMAN; HYPERSALIVATION; INSULIN RESISTANCE; INTELLECTUAL IMPAIRMENT; LETHARGY; METABOLIC SYNDROME X; PATIENT MONITORING; REVIEW; SIDE EFFECT; SLURRED SPEECH; TARDIVE DYSKINESIA; TIC; WEIGHT GAIN;

EID: 33845267496     PISSN: 10573291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Aman MG. Overview of pharmacotherapy: Current status and future directions. J Ment Defic Res 1987;31:121-130.
2. Aman MG, Singh NN. Pharmacological interventions. In: Matson JL, Malick SA (eds), Handbook of Mental Retardation. Elmsford, NY: Pergamon Press, 1983:317-337.
3. American Diabetes Association, American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. (free on-line at: www.diabetesjournals.org) Diabetes Care 2004;27:595-601.
4. Bodfish JW, Newell KM, Sprague RL, et al. Dyskinetic movement disorder among adults with mental retardation: Phenomenology and co-occurrence with stereotypy. Am J Ment Retard 1996;101:118-129.
5. Kalachnik JE. Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Ment Retard Dev Disabil Res Rev 1999;5:348-359.
6. Kalachnik JE, Sprague RL. The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. J Clin Psychol 1993;49:177-189.
7. Keltner NL. Biological persecptives. Metabolic syndrome: Schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006;42:204-207.
8. Schachter DC, Kleinman I. Psychiatrists' attitudes about and informed consent practices for antipsychotics and tardive dyskinesia. Psychiatr Serv 2004;55:714-717.